Pangaea
Meet Pangaea at the UK Pavilion (Hall B, Stand 2348).
Pangaea is a South San Francisco and London based provider of a novel AI-driven product for characterizing patients across 4,000 hard-to-diagnose conditions in a privacy-preserving and scalable manner, which is helping clinicians in the pharmaceutical and healthcare industry. Pangaea has clinically proven to discover 22x more undiagnosed, misdiagnosed and miscoded patients along with new insights; halve treatment costs; and drive sustainable collaborations between healthcare and the pharmaceutical industry. The founders (Dr. Vibhor Gupta, Prof. Yike Guo) have attracted $200 million through research and are advised by Lord David Prior (former Chairman of NHS England), Mr. Andy Palmer (former Head of Systems Integration at Novartis) and Dr. Thomas Dyrberg (former Managing Partner, Novo Holdings). Pangaea was awarded top tier status by Microsoft, which is exclusive for 30 of the 30,000 companies they work with and has provided the opportunity to apply its product across 140,000 healthcare providers globally.
Phaim
Meet Phaim at the UK Pavilion (Hall B, Stand 2348).
Phaim is developing novel therapies for the treatment and early detection of autoimmune disease with a lead product in Type1 Diabetes. Phaim’s platform approach to autoimmunity will recapitulate the normal regulatory immune response, preventing the onset of T1DM in prediabetics, and facilitating the use of cellular therapies in the treatment of established T1DM patients. The platform has means of identifying targets in other autoimmune diseases, such as psoriasis and we would look to produce other therapies after our successful T1DM trial. Furthermore, with our proprietary diagnostic kit, we will be able to predict who is likely to get T1DM and in what time frame. By doing so, we could potentially treat before the disease develops and look to ameliorate the need for insulin. In short, Phaim canpredict, prevent and potentially treattype 1 diabetes and other autoimmune conditions. Phaim's T1D therapy alone has a potential of world-wide market capture.
